Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer

Lung Cancer

Volumn 66, Issue 2, 2009, Pages 226-230

  Zarogoulidis, K ^a   Mylonaki, E ^b   Kakavelas, P ^b   Zarogoulidis, P ^a   Tsiouda, Th ^a   Rapti, E ^c   Lithoxopoulou, H ^a   Zarogoulidou, V ^a   Kontakiotis, Th ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b G PAPANICOLAOU HOSPITAL   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Carboplatin; Drug treatment; Etoposide; First line chemotherapy; Small cell lung cancer (SCLC); Topotecan

Indexed keywords

CARBOPLATIN; ETOPOSIDE; PLATINUM COMPLEX; RECOMBINANT ERYTHROPOIETIN; TOPOTECAN;

ADRENAL METASTASIS; ADULT; ANEMIA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER METASTASIS; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKULL IRRADIATION; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; SMALL CELL LUNG CARCINOMA; TOPOTECAN; TREATMENT OUTCOME;

EID: 70350303224     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.02.003     Document Type: Article

References (39)

1. Schiller J.H., Kim K., Hutson P., DeVore R., Glick J., Stewart J., et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J Clin Oncol 14 (1996) 2345-2352
2. Whitacre C.M., Zborowska E., Gordon N.H., Mackay W., and Berger N.A. Topotecan increases topoisomerase IIα levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res 57 (1997) 1425-1428
3. Slevin M.L., Clark P.I., Joel S.P., Malik S., Osborne R.J., Gregory W.M., et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7 (1989) 1333-1340
4. Miller A.A., Herndon J.E., Hollis D.R., Ellerton J., Langleben A., Richards F., et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 13 (1995) 1871-1879
5. Miquel Taron, Carmen Plasencia, Albert Abad, Cristina Martin, and Mónica Guillot. Cytotoxic effects of topotecan combined with various active G 2/M phase anticancer drugs in panel of human tumor derived cell lines. Ann Oncol 9 Suppl. 4 (1998) 135 [Abstract 647]
6. Bonner J.A., and Kozelsky T.F. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother Pharmacol 39 (1996) 109-112
7. Kaufmann S.H., Peereboom D., Buckwalter C.A., Svingen P.A., Grochow L.B., Donehower R.C., et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88 (1996) 734-741
8. Rowinsky E.K., Kaufmann S.H., Baker S.D., Grochow L.B., Chen T.L., Peereboom D., et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 14 (1996) 3074-3084
9. De Jonge M.J.A., Loos W.J., Gelderblom H., Planting A.S.T., van der Burg M.E.L., Sparreboom A., et al. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. J Clin Oncol 18 (2000) 2104-2115
10. Shifflett S., McCune J., Faucette S., Donahue A., Gillenwater H., Ma M., et al. Therapeutic drug monitoring (TDM) for topotecan in combination with carboplatin (P) and etoposide (E) for extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 19 (2000) 188a [Abstract 732]
11. Gillenwater H.H., Mc Cune J.S., Lindley C., Stewart C.F., Faucette S., Zamboni W.C., et al. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with carboplatin and etoposide in extensive stage small cell lung cancer. Cancer Invest 23 (2005) 511-519
12. Maksymiuk A.W., Jett J.R., Earle J.D., Su J.Q., Diegert F.A., Mailliard J.A., et al. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group Randomized Clinical Trial. J Clin Oncol 12 (1994) 70-76
13. Seifart U., Jensen K., Ukena J., Mueller C., Schröder M., Fuhr H.G., et al. Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC). Lung Cancer 48 3 (2005) 415-422
14. Baker S.D., Heidemann R., Jones D., et al. Clinical pharmacodynamics of continuous infusion of topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 37 (1996) 195-202
15. Stewart C.F., Baker S.D., Heidemann R., Jones D., Crom W.R., and Pratt CB. Clinical pharmacodynamics of continuous infusion of topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 12 (1994) 1946-1954
16. Herben V.M.M., ten Bokkel Huinink W.W., and Beijnen J.H. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 31 (1996) 85-102
17. Ardizzoni A., Hansen H., Dombernowsky P., Gamucci T., Kaplan S., Postmus P., et al. Topotecan, a new active drug in the second-line treatment of small cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 15 (1997) 2090-2096
18. Von Pawel J., Gatzemeier U., Pujol J.-L., Moreau L., Bildat S., Ranson M., et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 19 (2001) 1743-1749
19. Licitra E.J., Vyas V., Nelson K., Musanti R., Beers S., Thomas C., et al. Phase I clinical evaluation of sequential topoisomerase targeting in combination with cisplatin in the treatment of patients with advanced solid tumors. Clin Cancer Res 9 (2003) 1673-1679
20. Hammond L.A., Eckardt J.R., Ganapathi R., Burris H.A., Rodriguez G.A., Eckhardt S.G., et al. A phase I translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. Clin Cancer Res 4 (1998) 1459-1467
21. Miller A.A., Omari A.A., Murry D.J., and Case D. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer. Lung Cancer 54 3 (2006) 379-385
22. Mavroudis D., Veslemes M., Kouroussis Ch, Tzanakis N., Ferdoutsis E., Toubis M., et al. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. Lung Cancer 38 (2002) 59-63
23. Schiller J.H., Adak S., Cella D., DeVore R.F., and Johnson D.H. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19 8 (2001) 2114-2122
24. Eckardt J.R., von Pawel J., Papai Z., Tomova A., Tzekova V., Crofts T.E., et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 24 13 (2006) 2044-2051
25. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared to etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 (2002) 85-91
26. Gervais R., Quoix E., Breton J.L., Mattson K., Wilson J., Ross G., et al. A randomized phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Lung Cancer 49 (2005) 253-261
27. Reck M., Groth G., Buchholz E., Goetz E., Gatzemeier U., and Manegold C. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen. Lung Cancer 38 3 (2005) 409-414
28. Carney DN, Shepherd FA. Treatment of SCLC: chemotherapy. In: Hansen HH, editor. Text Book of Lung Cancer (IASCL), 2000. p. 261-72.
29. Grossi F., Scolaro T., Tixi L., Loprevite M., and Ardizzoni A. The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer. Crit Rev Oncol/Hematol 37 (2001) 61-67
30. Kristjansen P.E.G., Soelberg Søorensen P., Skov Hansen M., and Hansen H.H. Prospective evaluation of the effect on initial brain metastases from small cell lung cancer of platinum-etoposide based induction chemotherapy followed by alternating multidrug regimen. Ann Oncol 4 7 (1993) 579-583
31. Kristjansen P.E.G., and Hansen H.H. Brain metastasis from small cell lung cancer treated with combination chemotherapy. Eur J Cancer Clin Oncol 24 (1988) 545-549
32. Giaccone G., Donadio M., Bonardi G.M., Testore F., and Calciati A. Teniposide (VM 26): an effective treatment for brain metastases of small cell lung cancer carcinoma of the lung. Eur J Cancer Clin Oncol 24 (1988) 629-631
33. Postmus P.E., Haaxma-Reiche H., Vencken L.M., Meinesz A.F., Sleijfer DTh, and Mulder N.H. High dose etoposide for brain metastases of small cell lung cancer. A phase II study. Br J Cancer 59 (1989) 254-256
34. Groen H.J.M., Smit E.F., Haaxma-Reiche H., and Postmus P.E. Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer. Eur J Cancer 29A (1993) 1696-1699
35. Malacarne P., Santini A., and Maestri A. Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide. Oncology 53 (1996) 210-213
36. Kaba S.E., Kyritsis A.P., Hess K., Yung W.K., Mercier R., Dakhil S., et al. TDPC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 15 (1997) 1063-1070
37. Zarogoulidis K, Chatzopoulou A, Kontakiotis T, Theodoridis G, Pousinis P, Patakas D. Predisposing factors of blood brain barrier penetration from docetaxel during lung cancer treatment: preliminary study. J Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol. 24, no. 18S (June 20 Supplement), 2006, p. 17102.
38. Bunn P.A., Nugent J.L., and Matthews M.J. Central nervous system metastases in small cell brochogenic carcinoma. Semin Oncol 5 (1978) 314-322
39. Neijstrom E.S., Capizzi R.L., and Rudnick S.A. High-dose methotrexate in small cell lung cancer. Lack of efficacy in preventing CNS relapse. Cancer 51 (1983) 1056-1061